2014-05-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/647790摘要：慢性阻塞性肺疾病（COPD）是一個重大的公共衛生問題，主要是由吸菸所引起的。 2004年，慢性阻塞性肺病導致全球 275萬人亡，為全世界主要死亡原因第四位。儘管吸菸率在過去的幾十年間逐漸下降，慢性阻塞性肺病所造成的死亡仍大幅上升。慢性阻塞性肺病無法治癒，治療只能緩解症狀。目前，迫切需要開發有效與新的方法來預防和治療慢性阻塞性肺病。在台灣，儘管慢性阻塞性肺病也是常見的疾病，而且也消耗大量的醫療花費（2005 年約 24 億新台幣），但是與其他常見疾病比較，如高血壓或糖尿病，慢性阻塞性肺病仍缺乏前瞻性的全國性的流行病學研究或臨床試驗。 台灣慢性阻塞性肺病聯盟（TCoC）是由多位胸腔科的專家醫師所組成，他們在慢性阻塞性肺病的領域有豐富的基礎實驗和臨床研究經驗。 TCoC 重要任務是協助設計和進行多中心（研究者發起或由國際研究組織與藥廠發起）的臨床試驗，以及建立慢性阻塞性肺病患者的資料庫。TCoC 中心辦公室提供訊息聯繫，資料庫維護和核心研究的協調窗口。 TCoC 核心設施提供臨床研究者進行候選基因的 SNP 分析以及胸腔電腦斷層影像分析。參與者需要簽署知情同意書來提供臨床資訊，影像，血液/血漿/血清/灌洗液存儲和基因 SNP 分析。病人的臨床資料會使用網路建置的系統加以收集供日後分析使用。 台灣慢性阻塞性肺病聯盟有能力每年招收大約 700-800 慢性阻塞性肺病患者。然而，TCoC最終的目標是推動有治療潛力的慢性阻塞性肺病臨床試驗，並加速治療方法發展的速度，使慢性阻塞性肺病患者的壽命得以延長，生活品質獲得改善。目前，許多由國際性藥廠與本地業者委託的臨床試驗與研究案已藉由 TCoC建立的機制以及 TCoC的成員醫院合作進行中。<br> Abstract: Chronic obstructive pulmonary disease (COPD) is a major public health problem mainly caused by cigarette smoking. In 2004, COPD causes 2.75 million deaths worldwide, representing the fourth leading cause of death. Mortality due to COPD has risen sharply over the past several decades despite a major decline in smoking prevalence. There is no cure for COPD, treatments are only relieve symptoms in moderate effectiveness. Novel approaches to prevent and treat COPD are urgently needed. Although COPD is also a common disease in Taiwanese population and consumes a large amount of health care expenditure (about 2,400 million NTD in 2005), studies regarding longitudinal, prospective nationwide epidemiology, or intervention are lacking compared to other common diseases, such as hypertension, or diabetes. The participating investigators of Taiwan COPD consortium (TCoC) are specialists of pulmonary medicine who have plenty of experience in conducting bench and clinical studies of COPD. The key missions of the TCoC are to assist the design and conduct of multi-center (investigator-initiated, industry or international research groups) clinical trials, as well as the establishment of a biospecimen database of COPD. Central office provides the window of communication, database maintenance and core study coordination. The core facilities of TCoC will provide candidate genes SNP analysis and computed tomography image analysis under a collaborative clinical research. Participating subjects need to sign the informed consent for clinical data, thoracic image, PBMC/plasma/serum/ lavage fluids storage and gene SNP analysis. Core clinical information is collected using a web based information system for future analysis. Generally, the consortium is expected to enroll 700-800 COPD patients per year. The ultimate goal for TCoC is to enable clinical trials of potential therapies for COPD and speed the development of treatments that will improve the length and quality of life for patients with COPD. Currently, many clinical trials sponsored by global and regional pharmaceutical companies are designed and conducted through the infrastructure of TCoC, and collaboration among TCoC members.